Free Trial

Resolute Capital Asset Partners LLC Buys 53,000 Shares of Ascendis Pharma A/S $ASND

Ascendis Pharma A/S logo with Medical background

Key Points

  • Resolute Capital Asset Partners LLC increased its stake in Ascendis Pharma A/S by 46.3%, acquiring an additional 53,000 shares to hold a total of 167,500 shares, which represents 14.7% of its portfolio.
  • Ascendis Pharma A/S has received multiple ratings upgrades from analysts, with price targets raised by firms such as Wedbush and Bank of America, indicating a consensus "buy" rating and an average target price of $243.36.
  • The company reported revenues of $216.28 million for its most recent quarter, surpassing analyst expectations, and its earnings per share (EPS) of ($0.93) was better than the anticipated (1.42).
  • Five stocks to consider instead of Ascendis Pharma A/S.

Resolute Capital Asset Partners LLC increased its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 46.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 167,500 shares of the biotechnology company's stock after acquiring an additional 53,000 shares during the period. Ascendis Pharma A/S comprises about 14.7% of Resolute Capital Asset Partners LLC's portfolio, making the stock its largest position. Resolute Capital Asset Partners LLC owned about 0.27% of Ascendis Pharma A/S worth $26,107,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth $28,000. Brooklyn Investment Group raised its holdings in shares of Ascendis Pharma A/S by 332.9% during the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 273 shares during the period. Quarry LP acquired a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth $96,000. Tower Research Capital LLC TRC raised its holdings in shares of Ascendis Pharma A/S by 195.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,004 shares of the biotechnology company's stock worth $138,000 after acquiring an additional 664 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Ascendis Pharma A/S during the fourth quarter worth $174,000.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ASND. Oppenheimer restated an "outperform" rating and set a $224.00 price objective (up from $215.00) on shares of Ascendis Pharma A/S in a report on Friday, June 13th. Wells Fargo & Company restated an "overweight" rating and set a $295.00 price objective (up from $289.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Morgan Stanley initiated coverage on shares of Ascendis Pharma A/S in a report on Thursday, July 3rd. They set an "overweight" rating and a $250.00 price objective on the stock. Wall Street Zen upgraded shares of Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Bank of America lifted their price target on shares of Ascendis Pharma A/S from $201.00 to $216.00 and gave the company a "buy" rating in a research note on Monday, June 9th. Fifteen research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $243.36.

View Our Latest Report on ASND

Ascendis Pharma A/S Stock Up 1.2%

Shares of ASND stock traded up $2.22 on Thursday, reaching $195.23. The stock had a trading volume of 219,684 shares, compared to its average volume of 491,322. The firm's 50-day moving average is $179.38 and its two-hundred day moving average is $164.88. The firm has a market capitalization of $11.95 billion, a price-to-earnings ratio of -37.84 and a beta of 0.41. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $199.99.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.42) by $0.49. The firm had revenue of $216.28 million during the quarter, compared to the consensus estimate of $163.17 million. On average, sell-side analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

(Free Report)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

See Also

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Should You Invest $1,000 in Ascendis Pharma A/S Right Now?

Before you consider Ascendis Pharma A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.

While Ascendis Pharma A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.